Inhibitors of ACK1/TNK2 tyrosine kinase
Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.
1. A compound having Formula III:
wherein
n is 1, 2, or 3;
and
R 1 is cyclopentyl, cyclohexyl, furanyl, pyrrolidinyl, oxanyl, phenyl, or pyrimidinyl, any of which are unsubstituted or substituted with Cl, Br, F, C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl;
R 2′ is H, Cl, Br, F, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 1 is cyclopentyl, cyclohexyl, furanyl, pyrrolidinyl, oxane, any of which is optionally substituted with C 1 -C 6 alkyl.
3. The compound of claim 1 , wherein R 1 is phenyl optionally substituted with Cl or F.
4. The compound of claim 1 , wherein R 2′ is H or OMe.
5. A compound chosen from
6. A method of treating prostate cancer in a subject, comprising administering to the subject an effective amount of a compound of claim 1 .
7. A method comprising contacting a prostate tumor cell with an effective amount of a compound of claim 1 .
8. A method of treating prostate cancer in a subject, comprising administering to the subject an effective amount of a compound of claim 5 .
9. A method comprising contacting a prostate tumor cell with an effective amount of a compound of claim 5 .